Mereo BioPharma
MREO
24 hedge funds and large institutions have $22M invested in Mereo BioPharma in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.
543% more capital invested
Capital invested by funds: $3.42M → $22M (+$18.6M)
500% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 2
71% more funds holding
Funds holding: 14 → 24 (+10)
3.21% more ownership
Funds ownership: 2.64% → 5.84% (+3.2%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$2.79M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$1.37M |
| 3 |
Verition Fund Management
Greenwich,
Connecticut
|
+$697K |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$662K |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$471K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$187K |
| 2 |
Primecap Management
Pasadena,
California
|
-$95.8K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$35.3K |
| 4 |
WANY
Wealthspire Advisors (New York)
New York
|
-$15K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.51K |
MREO Hedge Fund Activity: Q2 2020 in Review
24 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2020, worth a combined $22M — up 543% from $3.42M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new MREO positions and 2 closed out — a net gain of 10 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Boxer Capital, adding an estimated $2.79M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $187K sold.
- 24 institutional investors held Mereo BioPharma (MREO) as of Q2 2020, up from 14 in Q1 2020.
- Funds reported $22M of Mereo BioPharma stock for Q2 2020, up 543% quarter-over-quarter.
- 12 funds opened new Mereo BioPharma positions in Q2 2020 and 2 closed out, a net change of +10 holders.
- The largest Mereo BioPharma buyer in Q2 2020 was Boxer Capital, an estimated $2.79M added.
- The largest Mereo BioPharma seller in Q2 2020 was Perceptive Advisors, an estimated $187K sold.
Based on aggregated 13F filings for Q2 2020.